Abstract
Background: The growth of economic analyses and in particular cost-utility analyses (CUA), which use the QALY as a measure of outcome, has heightened the interest in the methodologies used to calculate the QALY. The EQ-5D has produced quite different utility values from that of the SF-6D. This article seeks to understand these differences using a cohort of patients with inflammatory arthritis.
Objective: To examine the relationship between the disease-specific measure, Health Assessment Questionnaire (HAQ) disability index (DI) and the preference-based measures, SF-6D, EQ-5D and European League Against Arthritis (EULAR) Disease Activity Score (DAS) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
Methods: Patients with RA and PsA (n = 504) attending a tertiary rheumatology referral centre completed the HAQ, SF-6D and the EQ-5D before starting biological therapy and again 12 months later. The SF-36 was converted into a utility using the preference-based SF-6D. Clinical outcomes such as the DAS, joint counts and laboratory measures were also recorded. We calculated single index utility scores from the preference-based instruments using UK population norms. We used regression analysis to derive a mapping function and calculated utility scores from the HAQDI and the DAS 28.
Results: The mean utility observed at baseline for RA was 0.43 for the EQ-5D and 0.54 for the SF-6D and for PsA was 0.49 for the EQ-5D and 0.57 for the SF-6D. The utility gain demonstrated by the EQ-5D was over twice that of the SF-6D. The EQ-5D scored 17% of the RA group as less than 0 (state defined as worse than death); 7% of this group remained less than 0 at followup. The distribution of the utility estimates was similar for both RA and PsA.
Conclusions: Our findings draw attention to the impact of states worse than death on the overall distribution for the EQ-5D derived utilities and how these impact on its use in practice. EQ-5D-derived QALY changes are over twice that of the SF-6D. The implication of this for decision makers is that cost-effectiveness evaluations for treatments in this disease class are likely to be very sensitive to the choice of utility measure.
Similar content being viewed by others
References
Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. The National Arthritis Data Work Groups. Arthritis Rheum 1995; 38 (10): 1351–62
Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics 2008; 26 (2): 121–9
van Gestel AM, Prevoo ML, van ’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39 (1): 34–40
Hurst N, Jobanputra P, Hunter M, et al. Validity of Euro-QoL: a generic health status instrument in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Rheumatology (Oxford) 1994; 33 (7): 655–62
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83
Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcomes in arthritis. Arthritis Rheum 1980; 23: 137–45
Bryan S, Longworth L. Measuring health-related utility: why the disparity between EQ-5D and SF-6D? Eur J Health Econ 2005; 6 (3): 253–60
Seymour J, McNamee P, Scott A, et al. Shedding new light onto the ceiling and floor? A quantile regression approach to compare EQ-5D and SF-6D responses. Health Econ. Epub 2009 Jun 5
Lamers L, Bouwmans C, van Straten A, et al. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ 2006; 15 (11): 1229–36
Gerard K, Nicholson T, Mullee M, et al. EQ-5D versus SF- 6D in an older, chronically ill patient group. Appl Health Econ Health Policy 2004; 3 (2): 91–102
Kobelt G, Lindgren P, Lindroth Y, et al. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44 (9): 1169–75
Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347–56
Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004; 43 (1): 62–72
Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004; 8 (11): iii, 1–91
Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005; 64 (7): 995–1002
Tanno M, Nakamura I, Ito K, et al. Modeling and costeffectiveness analysis of etanercept in adultswith rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 2006; 16 (2): 77–84
National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008
Bansback N, Marra C, Tsuchiya A, et al. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Care Res 2007; 57 (6): 963–71
Harrison MJ, Lunt M, Bansback N, et al. The validity of estimating EQ-5D and SF-6D utility values from the HAQ. American College of Rheumatology Annual Meeting; 2008 Oct 24-29; San Francisco (CA)
Barton GR, Sach TH, Jenkinson C, et al. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes 2008; 6: 51
Craig BM, Busschbach JJ. The episodic random utility model unifies time trade-off and discrete choice approaches in health state valuation. Popul Health Metr 2009; 7: 3
van Riel P, van Gestel A, van de Putte L. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996; 35 Suppl. 2: 4–7
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21 (2): 271–92
Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
Kharroubi S, Brazier JE, O’Hagan A. Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method. Soc Sci Med 2007; 64 (6): 1242
University of Sheffield, Health Economics and Decision Science. Bayesian programme [online]. Available from URL: http://www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d/bayesian.html [Accessed 2009 Dec 1]
Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010 Jan; 69 (1): 222–5
Lindgren P, Geborek P, Kobelt G. Modelling the costeffectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care 2009; 25 (02): 181–9
Hurst N, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatology (Oxford) 1997; 36 (5): 551–9
Marra C, Esdaile JM, Guh D, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004; 42 (11): 1125–31
Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996; 5 (2): 141–54
EQ-5D: a standardised instrument for use as a measure of health outcome [online]. Available from URL: http://www.euroqol.org [Accessed 2009 Sep 1]
Fries J, Spitz P, Young D. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9 (5): 789–93
National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 1994
Pharmaceutical Benefits Board. General guidelines for economic evaluation from the Pharmaceutical Benefits Board. 2003 [online]. Available from URL: http://www.tlv.se [Accessed 2010 Feb 23]
Rovira J, Antoñanzas F. Economic analysis of health technologies and programmes: a Spanish proposal for methodological standardisation. Pharmacoeconomics 1995; 8 (3): 245–52
The AMCP Format for Formulary Submissions (version 3.0). Alexandria (VA): Foundation for Managed Care Pharmacy, 2009 Oct
Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-a inhibitors in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. An independent report. Rheumatology (Oxford) 2007; 46: 1345–54
Harrison MJ, Davies LM, Bansback NJ, et al. Why do patients with inflammatory arthritis often score states ‘worse than death’ on the EQ-5D? An investigation of the EQ-5D classification system. Value Health 2009 Sep; 12 (6): 1026–34
Marra CA, Rashidi AA, Guh D, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005; 14 (5): 1333
Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preference- based instruments. Med Care 2003; 41 (7): 791–801
Harrison MJ, Davies LM, Bansback NJ, et al. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res 2009 Nov; 18 (9): 1195–205
Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001; 45 (2): 151–8
Bansback NJ, Ara R, Barkham N, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 2006; 45 (8): 1029–38
Kielhorn A, Porter D, Diamantopoulos A, et al. UK costutility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin 2008; 24 (9): 2639–50
Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 781–96
Acknowledgements
No funding was received for this study.
Professor Veale has received research grants from Wyeth Pharmaceuticals, Schering Plough and GlaxoSmithKline, and consulting fees from Wyeth Pharmaceuticals and Schering Plough. Professor FitzGerald has received a research grant from Abbott Immunology Pharmaceuticals and is a speaker for Wyeth Pharmaceuticals, Abbott Immunology Pharmaceuticals and Bristol Myers Squibb.
The authors thank Dr C.T. Ng, Dr Adrian Gibbs, Dr Bernadette Lynch and Dr Tajvur Saber for their assistance in collecting these data.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Adams, R., Walsh, C., Veale, D. et al. Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis. Pharmacoeconomics 28, 477–487 (2010). https://doi.org/10.2165/11533010-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11533010-000000000-00000